Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.

MATRIX BUYS 55 PC STAKE IN CONCORD BIOTECH

Pharmaceutical company Matrix Laboratories Ltd today said it has acquired 55
per cent stake in biotechnology company Concord Biotech Ltd for an undisclosed
sum as part of its strategy to acquire fermentation technology and manufacturing
capabilities. Hyderabad-based Matrix said the acquisition of a controlling stake
of 55 per cent was aimed at adding to its technology and manufacturing strengths
to utilise the market potential of the fermentation technology-based products
of Concord, by leveraging its strong customer base and marketing strengths in
the global generic markets.